Wandercraft Announces Availability of Atalante X in Australia Following Therapeutic Goods Administration (TGA) Approval
Paris, France / Sydney, Australia — February 24th, 2026 — Wandercraft, a global leader in self-balancing robotic mobility systems, today announced that Atalante X, its hands-free exoskeleton designed for rehabilitation, is now available in Australia following inclusion on the Australian Register of Therapeutic Goods (ARTG) as a Class IIa medical device. The TGA approval marks Wandercraft’s latest regulatory milestone, following expanded clearances from both the U.S. Food and Drug Administration (FDA) and European regulators (CE-mark).
Atalante X is used in rehabilitation settings to help people with walking impairments practice standing and walking in a safe, supported way. Under the guidance of trained healthcare professionals, patients can walk upright and hands-free as part of their rehabilitation journey. This hands-free capability – unique among clinical exoskeletons – enables more natural movement while reducing physical strain on therapists.
In Australia, Atalante X will be distributed by NeuroNova Robotics, a specialist provider of advanced rehabilitation and assistive technologies and the local ARTG sponsor for the device. The first Atalante X will be available for clinical use in Melbourbe via PhysioNXT as early as July 2026.
“Making Atalante X available in Australia is an important step in expanding access to more patients who want to spend more time upright, walking, and pushing their movement goals in a rehabilitation context,” said Matthieu Masselin, CEO and co-founder of Wandercraft. “We are proud to work alongside NeuroNova Robotics to support rehabilitation teams as they explore new ways to help patients practice upright walking in a controlled clinical environment.”
Atalante X is already used in over 100 leading rehabilitation and research centers worldwide to support gait training for people with severe mobility impairments. Recent clinical and real-world studies have demonstrated strong usability, integration into routine care, and high engagement across diverse patient profiles, including stroke, spinal cord injury, and other complex neurological conditions.
Recent milestones
Wandercraft’s presence in the global healthcare landscape continues to grow, marked by a series of recent milestones. In 2025, Atalante X earned an expanded clearances from the FDA and CE-mark that broadened its intended use to include individuals with a wider range of injuries and neurological conditions, reflecting a significant advance in clinical access and therapeutic flexibility.
The system is now used in more than 100 rehabilitation and research centers worldwide, supporting intensive gait training and contributing to over 1 million steps taken per month in therapy sessions.
Wandercraft continues to publish real-world case study data demonstrating effective integration of Atalante X into clinical workflows and showcased its capabilities at major professional gatherings such as the American Congress of Rehabilitation Medicine 2025, where clinicians reported high engagement across diverse patient profiles. These achievements underscore Wandercraft’s ongoing commitment to moving robotic rehabilitation from innovation to real-world impact.
Paving the pathway towards home mobility
Looking beyond the clinic, Wandercraft is preparing to launch Eve, its self-balancing exoskeleton for home use, to the U.S. later this year. Designed to support people as they continue their walking journey, Eve builds on the same hands-free technology behind Atalante X and extends it beyond rehabilitation into everyday life.
Eve reflects Wandercraft’s long-term vision of helping people to not just walk in rehabilitation but reclaim the benefits of upright mobility in everyday life. Together, Atalante X and Eve form a continuum – from clinic to home – that redefines what is possible in mobility care.
Australian rehabilitation centers and healthcare professionals interested in learning more about Atalante X, including clinical use and availability, you can email info@neuronovarobotics.com.au or visit www.neuronovarobotics.com.au.
For more information or to learn about Eve, please contact: us-sales@wandercraft.health